Detection of aberrant p16 methylation in the serum of colorectal cancer patients

Hong Zhi Zou, Bao Ming Yu, Zhi Wei Wang, Ji Yuan Sun, Hui Cang, Fei Gao, Dong Hua Li, Ren Zhao, Guo Guang Feng, Jing Yi

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Purpose: This study was designed to detect aberrant p16 promoter methylation in the serum of patients with colorectal cancer (CRC) and to explore the possibility of using this assay in early detection or as a prognostic marker of CRC patients. Experimental Design: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and matching serum samples and control serum samples from 34 patients with adenomatous polyps and 10 healthy individuals. The association of p16 hypermethylation in serum DNA of CRC patients with clinicopathological characteristics was then analyzed. Results: P16 hypermethylation was found in 20 of 52 (38%) CRCs. Among the 20 cases with aberrant methylation in the tumor tissues, similar changes were also detected in the serum of 14 (70%) cases. No methylated p16 sequences were detected in the peripheral serum of the other 32 CRC cases without these changes in the tumor, in 34 patients with adenomatous polyps, or in 10 healthy control subjects. Clinicopathological analysis revealed that p16 methylation in serum was significantly associated with later Dukes' stage (P = 0.03). Conclusions: This assay offers a potential means for the serum-based detection and/or monitoring of CRC patients.

Original languageEnglish (US)
Pages (from-to)188-191
Number of pages4
JournalClinical Cancer Research
Volume8
Issue number1
StatePublished - 2002
Externally publishedYes

Fingerprint

Methylation
Colorectal Neoplasms
Serum
Adenomatous Polyps
DNA Methylation
Neoplasms
Healthy Volunteers
Research Design
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zou, H. Z., Yu, B. M., Wang, Z. W., Sun, J. Y., Cang, H., Gao, F., ... Yi, J. (2002). Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clinical Cancer Research, 8(1), 188-191.

Detection of aberrant p16 methylation in the serum of colorectal cancer patients. / Zou, Hong Zhi; Yu, Bao Ming; Wang, Zhi Wei; Sun, Ji Yuan; Cang, Hui; Gao, Fei; Li, Dong Hua; Zhao, Ren; Feng, Guo Guang; Yi, Jing.

In: Clinical Cancer Research, Vol. 8, No. 1, 2002, p. 188-191.

Research output: Contribution to journalArticle

Zou, HZ, Yu, BM, Wang, ZW, Sun, JY, Cang, H, Gao, F, Li, DH, Zhao, R, Feng, GG & Yi, J 2002, 'Detection of aberrant p16 methylation in the serum of colorectal cancer patients', Clinical Cancer Research, vol. 8, no. 1, pp. 188-191.
Zou HZ, Yu BM, Wang ZW, Sun JY, Cang H, Gao F et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clinical Cancer Research. 2002;8(1):188-191.
Zou, Hong Zhi ; Yu, Bao Ming ; Wang, Zhi Wei ; Sun, Ji Yuan ; Cang, Hui ; Gao, Fei ; Li, Dong Hua ; Zhao, Ren ; Feng, Guo Guang ; Yi, Jing. / Detection of aberrant p16 methylation in the serum of colorectal cancer patients. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 1. pp. 188-191.
@article{5572e13d033347f2b651d45062318c57,
title = "Detection of aberrant p16 methylation in the serum of colorectal cancer patients",
abstract = "Purpose: This study was designed to detect aberrant p16 promoter methylation in the serum of patients with colorectal cancer (CRC) and to explore the possibility of using this assay in early detection or as a prognostic marker of CRC patients. Experimental Design: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and matching serum samples and control serum samples from 34 patients with adenomatous polyps and 10 healthy individuals. The association of p16 hypermethylation in serum DNA of CRC patients with clinicopathological characteristics was then analyzed. Results: P16 hypermethylation was found in 20 of 52 (38{\%}) CRCs. Among the 20 cases with aberrant methylation in the tumor tissues, similar changes were also detected in the serum of 14 (70{\%}) cases. No methylated p16 sequences were detected in the peripheral serum of the other 32 CRC cases without these changes in the tumor, in 34 patients with adenomatous polyps, or in 10 healthy control subjects. Clinicopathological analysis revealed that p16 methylation in serum was significantly associated with later Dukes' stage (P = 0.03). Conclusions: This assay offers a potential means for the serum-based detection and/or monitoring of CRC patients.",
author = "Zou, {Hong Zhi} and Yu, {Bao Ming} and Wang, {Zhi Wei} and Sun, {Ji Yuan} and Hui Cang and Fei Gao and Li, {Dong Hua} and Ren Zhao and Feng, {Guo Guang} and Jing Yi",
year = "2002",
language = "English (US)",
volume = "8",
pages = "188--191",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Detection of aberrant p16 methylation in the serum of colorectal cancer patients

AU - Zou, Hong Zhi

AU - Yu, Bao Ming

AU - Wang, Zhi Wei

AU - Sun, Ji Yuan

AU - Cang, Hui

AU - Gao, Fei

AU - Li, Dong Hua

AU - Zhao, Ren

AU - Feng, Guo Guang

AU - Yi, Jing

PY - 2002

Y1 - 2002

N2 - Purpose: This study was designed to detect aberrant p16 promoter methylation in the serum of patients with colorectal cancer (CRC) and to explore the possibility of using this assay in early detection or as a prognostic marker of CRC patients. Experimental Design: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and matching serum samples and control serum samples from 34 patients with adenomatous polyps and 10 healthy individuals. The association of p16 hypermethylation in serum DNA of CRC patients with clinicopathological characteristics was then analyzed. Results: P16 hypermethylation was found in 20 of 52 (38%) CRCs. Among the 20 cases with aberrant methylation in the tumor tissues, similar changes were also detected in the serum of 14 (70%) cases. No methylated p16 sequences were detected in the peripheral serum of the other 32 CRC cases without these changes in the tumor, in 34 patients with adenomatous polyps, or in 10 healthy control subjects. Clinicopathological analysis revealed that p16 methylation in serum was significantly associated with later Dukes' stage (P = 0.03). Conclusions: This assay offers a potential means for the serum-based detection and/or monitoring of CRC patients.

AB - Purpose: This study was designed to detect aberrant p16 promoter methylation in the serum of patients with colorectal cancer (CRC) and to explore the possibility of using this assay in early detection or as a prognostic marker of CRC patients. Experimental Design: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and matching serum samples and control serum samples from 34 patients with adenomatous polyps and 10 healthy individuals. The association of p16 hypermethylation in serum DNA of CRC patients with clinicopathological characteristics was then analyzed. Results: P16 hypermethylation was found in 20 of 52 (38%) CRCs. Among the 20 cases with aberrant methylation in the tumor tissues, similar changes were also detected in the serum of 14 (70%) cases. No methylated p16 sequences were detected in the peripheral serum of the other 32 CRC cases without these changes in the tumor, in 34 patients with adenomatous polyps, or in 10 healthy control subjects. Clinicopathological analysis revealed that p16 methylation in serum was significantly associated with later Dukes' stage (P = 0.03). Conclusions: This assay offers a potential means for the serum-based detection and/or monitoring of CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=0036152815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036152815&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 188

EP - 191

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -